Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 29s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Integrative Oncology in Practice: Evaluating the Efficacy and Safety of Herbal-Conventional Therapeutic Synergy

Mamatha H S[1]*, Ashok Kumar BS[2], Disha N S[3]

[1]Department of Pharmaceutics, R. L. Jalappa College of Pharmacy, Sri Devaraj Urs Academy Of Higher Education And Research, Tamaka, Kolar – 563103, Karnataka,India.

[2]Department of Pharmacognosy, R. L. Jalappa College of Pharmacy, Sri Devaraj Urs Academy Of Higher Education And Research, Tamaka, Kolar – 563103, Karnataka, India.

[3]Department of Pharmaceutical Chemistry, R. L. Jalappa College of Pharmacy, Sri Devaraj Urs Academy Of Higher Education And Research, Tamaka, Kolar – 563103, Karnataka, India.

***Corresponding author:**

Mamatha H S

Department of Pharmaceutics, R. L. Jalappa College of Pharmacy, Sri Devaraj Urs Academy of Higher Education and Research, Tamaka, Kolar – 563103, Karnataka,India

Email ID: shreemamatha6@gmail.com

Cite this paper as: Mamatha H S, Ashok Kumar BS, Disha N S, (2025) Integrative Oncology in Practice: Evaluating the Efficacy and Safety of Herbal-Conventional Therapeutic Synergy. *Journal of Neonatal Surgery*, 14 (29s), 534-544.

ABSTRACT

Cancer continues to be a major public health problem worldwide, with rising incidence and death rates. Although traditional treatments, including chemotherapy, radiotherapy, immunotherapy, and targeted therapy, have effectively improved survival rates, their resulting toxicities, drug resistance, and cost underscore the importance of developing more integrative treatment modalities. Integrative oncology, the integration of evidence-based complementary care with standard medical practice, represents a potential solution to these shortcomings. Herbal medicine, based on traditional systems of medicine, has bioactive compounds including curcumin, resveratrol, quercetin, epigallocatechin gallate, berberine, withaferin A, and sulforaphane, all of which have anticancer activity by mechanisms such as induction of apoptosis, inhibition of angiogenesis, and immunomodulation. Although there is emerging evidence that combining herbal compounds with conventional therapies may enhance survival rates and minimize treatment-related side effects, the scientific evidence so far is limited to a meta-analysis of 14 clinical trials. The discipline, nonetheless, is challenged by regulatory heterogeneity, inadequate large-scale clinical trials, and possible herb-drug interactions. To achieve the complete potential of integrative oncology, rigorous, large-scale clinical studies and protocols of standardization must be addressed by research in the future. A patient-focused, evidence-driven model that integrates scientifically proven herbal treatments and mainstream cancer therapies can provide a more effective and safer approach to cancer care.

Keywords: *cancer, disease, conventional therapies, curcumin, quercetin, Herbal.*

1. INTRODUCTION

Cancer continues to be among the most insurmountable health issues globally, with rising incidence and mortality. The World Health Organization (WHO) estimates that cancer caused approximately 10 million deaths in 2020 and ranks as one of the major causes of mortality worldwide (1). The burden of the disease persists amid factors influencing population aging, lifestyle, and the environment. Traditional treatment regimens, such as chemotherapy, radiotherapy, immunotherapy, targeted therapy, and hormone therapy, have greatly enhanced survival and disease control rates (2). Yet, these treatment methods have serious side effects, such as major toxicities, drug resistance, expense, and compromised patient quality of life (3). In addition, access and cost barriers restrict the dissemination of these treatments, particularly to low- and middle-income countries, perpetuating inequalities in the treatment and outcome of cancer.In view of these restrictions, integrative oncology has developed as an optimistic strategy with a vision of synergizing mainstream cancer therapies with supplementary treatments like herbal medicine in order to optimize treatment efficacy at lower side effects (4). Integrative oncology recognizes the potential of traditional healing systems, such as Ayurveda, Traditional Chinese Medicine (TCM), and other native practices, that have employed medicinal plants for millennia to cure multiple diseases, including cancer (5). Herbal

medicine, which includes bioactive agents with anticancer activity, act through various mechanisms like induction of apoptosis, suppression of angiogenesis, immune system modulation, and augmentation of efficacy of conventional treatment. Emerging evidence indicates that the integration of herbal medicine with conventional cancer therapies has the ability to counteract chemotherapy-induced toxicity, inhibit drug resistance, and enhance the well-being of patients (6).The acceptance of herbal medicine into mainstream oncology has been gaining momentum from scientific research illustrating its ability to complement conventional therapies. A few plant-derived agents, including paclitaxel (Taxol) of the Pacific yew tree and vincristine of the Madagascar periwinkle, have been effectively integrated into standard cancer therapy (7). Moreover, phytochemicals like curcumin, resveratrol, and quercetin have shown considerable anticancer activity in preclinical and clinical research, augmenting the action of chemotherapy and radiotherapy and reducing their toxicity (8, 9). However, for all these promising results, reservations persist regarding insufficient standardized dosing, risk of herb-drug interactions, and the requirement of further broad-scale clinical testing prior to adoption. This review proposes to discuss the synergistic value of an integrated approach using herbal and allopathic treatment for cancer therapy. It will offer a comparison of both the treatment modalities, explain their mechanisms of action, outline their strengths and limitations, and evaluate clinical evidence favoring integrative oncology. Through a careful review of existing research, the review aims to contribute to the developing discipline of integrative cancer care, and promote an evidence-based integration of herbal medicine with oncology. Future directions for research and clinical use will also be addressed to advance safer and more effective treatment strategies that maximize patient benefits.



Allopathic Cancer Therapies:

1. Chemotherapy

Chemotherapy administers cytotoxic agents systemically to kill rapidly proliferating malignant cells. The drugs induce apoptosis primarily by disrupting DNA replication or mitosis (11). Alkylating agents like cyclophosphamide and cisplatin create DNA cross-links that inhibit transcription and replication, leading to programmed cell death (12). Antimetabolites such as 5-fluorouracil and methotrexate are nucleotide mimics, inhibit DNA synthesis, and halt the cell cycle. Mitotic inhibitors like paclitaxel and vincristine interfere with microtubule dynamics, inhibiting normal chromosomal segregation and arresting cell division (13). Due to the lack of tumor selectivity of chemotherapy, normal proliferating tissues are also damaged, causing toxicities including myelosuppression, gastrointestinal damage, and organ injury.

2. RADIATION THERAPY



Fig 1: Radiation Therapy

Radiation therapy employs high-energy ionizing radiation to cause irreversible DNA double-strand breaks in cancer cells, resulting in cell-cycle arrest and apoptosis (14). Treatment options are external-beam radiation therapy (EBRT), where a targeted beam is aimed at the tumor, and brachytherapy, where radioactive implants are placed inside or near the lesion (15). Success is achieved by delivering maximal tumor dose with preservation of normal tissue. Highly sophisticated methods—e.g., intensity-modulated radiation therapy (IMRT) and proton therapy—enable sub-millimeter accuracy, minimizing collateral damage and enhancing outcomes (16). Radiation, however, remains capable of damaging adjacent structures, leading to fibrosis, organ dysfunction, or secondary malignancies.

3. IMMUNOTHERAPY

Immunotherapy utilizes host immunity to identify and kill tumor cells. Immune-checkpoint blockade—targeting inhibitory receptors like PD-1 and CTLA-4—resuscitates exhausted T cells; drugs like pembrolizumab (anti-PD-1) and ipilimumab (anti-CTLA-4) have revolutionized the treatment of melanoma, lung cancer, and other cancers (Pardoll 2012; Sharma & Allison 2015). Chimeric antigen receptor (CAR) T-cell therapy adapts a patient's T cells to bear artificial receptors that target tumor-specific antigens, achieving striking responses in some hematologic malignancies (17). Though dramatic successes have been achieved, response rates are variable and immune-related adverse effects—like colitis and pneumonitis—present management difficulties (18).

4. TARGETED THERAPY



Fig 2: Targeted Therapy

Targeted treatments interrupt oncogenic signaling cascades that promote tumor growth while avoiding most normal cells. Tyrosine-kinase inhibitors (TKIs) such as imatinib inhibit the BCR-ABL fusion protein in chronic myeloid leukemia, inhibiting uncontrolled proliferation (19). Monoclonal antibodies such as trastuzumab bind to HER2 in breast cancer, blocking receptor signaling and evoking immune cytotoxicity. Even better tolerated than conventional cytotoxics in general, targeted therapies are subject to resistance mechanisms—ranging from secondary mutations to pathway bypass—that constrain durability (20, 21). Current research addresses combination regimens and next-generation inhibitors to circumvent resistance.

5. HORMONE THERAPY



Fig 3: Hormone Therapy

Hormone-dependent tumors—breast and prostate most prominently—are treated by endocrine manipulation. Selective estrogen-receptor modulators like tamoxifen interfere with estrogen binding to estrogen receptors (ERs) in ER-positive breast cancer, inhibiting tumor growth (22, 23). Aromatase inhibitors (e.g., letrozole) also decrease estrogen production, and androgen-deprivation therapy (ADT) with drugs like leuprolide decreases testosterone in prostate cancer (24). Benefits are considerable, but side effects—such as osteoporosis, cardiovascular risk, and metabolic alterations—are still issues (25).

6. STEM-CELL TRANSPLANTATION (BONE-MARROW TRANSPLANT)

After high-dose chemotherapy or radiation, infusion of the hematopoietic stem cells can restore marrow function, a technique central to the treatment of leukemias, lymphomas, and multiple myeloma (26). Transplants can be autologous (derived from the patient) or allogeneic (donor-derived). Allogeneic procedures yield graft-versus-tumor effects but risk graft-versus-host disease (GVHD), where donor immune cells attack recipient tissues and may cause serious complications (27, 28).

7. HYPERTHERMIA THERAPY



Fig 4: Hyperthermia Therapy

Hyperthermia subjects tumors to 40 – 45 °C (104 – 113 °F) temperatures, directly causing cancer-cell apoptosis and tumor radiosensitization and chemosensitization (29). Methods are microwave hyperthermia and radio-frequency ablation, used in

tumors in organs like liver, breast, and prostate (30). Accurate temperature control is essential; excessive heat can damage nearby normal structures, while suboptimal heating diminishes therapeutic efficacy.

8. PHOTODYNAMIC THERAPY (PDT)

Photodynamic therapy involves a photosensitizing drug and light of a defined wavelength; when excited, the photosensitizer forms reactive oxygen species that selectively kill cancer cells (31). PDT is indicated for some skin, esophageal, and lung malignancies. Due to limited light penetration, deeply located tumors are less responsive, and photosensitivity in patients is transient. Future research continues to improve photosensitizer chemistry and light-delivery systems with the goal of extending PDT's use.

Bioactive Herbal Compounds in Cancer Therapies:

Herbal medicine has been practiced for millennia as an integral component of ancient health systems like Ayurveda, Traditional Chinese Medicine (TCM), and indigenous systems of medicine to treat and prevent numerous diseases, including cancer. Various plant-based drugs have demonstrated great anticancer activity, and these are now being integrated into modern oncology either as treatment agents directly or as an adjunct to conventional treatment. The anticancer efficacy of herbal medicine is because of its diverse bioactive constituents, which target multiple mechanisms of tumor growth, drug resistance, and immune modulation.

1. Curcumin (Turmeric - Curcuma longa)

Fig 5: Turmeric - Curcuma longa

Curcumin, the polyphenolic molecule derived from turmeric (Curcuma longa), is studied widely for its anticancer effect. Curcumin has been reported to exhibit anti-inflammatory, antioxidant, and anti-proliferative effects through the modulation of various molecular targets, including nuclear factor-kappa B (NF-κB), cyclooxygenase-2 (COX-2), and mitogen-activated protein kinase (MAPK) pathways. Curcumin induces apoptosis in cancer cells by upregulating pro-apoptotic proteins such as Bax and downregulating anti-apoptotic proteins such as Bcl-2. Curcumin also inhibits angiogenesis by suppressing VEGF signaling, thus curbing the vascularization of the tumor. Curcumin also enhances chemotherapy efficacy and reduces drug resistance, and hence it is an effective adjuvant in cancer therapy (33,34)

2. Resveratrol (Grapes - Vitis vinifera)

Fig 6: Grapes - Vitis vinifera

Resveratrol, a natural polyphenol found in grapes, berries, and peanuts, has exhibited anticancer activity of wide spectrum.

It exerts its anticancer effect through multiple mechanisms, i.e., inhibition of cell proliferation, induction of apoptosis, and modulation of inflammatory and oxidative stress pathways. Resveratrol activates tumor suppressor genes like p53 and interferes with oncogenic signaling pathways like phosphoinositide 3-kinase (PI3K)/Akt and mammalian target of rapamycin (mTOR). It also enhances the effectiveness of chemotherapy and minimizes its side effects, e.g., cardiotoxicity in doxorubicin treatment (35-37).

3. Quercetin (Onion)

Fig 7: Onion

Quercetin is a flavonoid found in onions, apples, and tea that is known for its potent antioxidant and anticancer activities. Quercetin induces apoptosis in cancer cells through the modulation of essential apoptosis proteins such as caspases and Bcl-2 family proteins. Quercetin inhibits angiogenesis through the downregulation of VEGF and matrix metalloproteinases (MMPs), metastasis, and invasion of tumors. Besides that, it has also been reported to modulate drug resistance by inhibiting efflux transporters such as P-glycoprotein (P-gp), thereby enhancing the efficacy and bioavailability of chemotherapeutic drugs (38-40).

4. Epigallocatechin Gallate (EGCG) (Camellia sinensis Green Tea)

Fig 8: Camellia sinensis Green Tea

EGCG, the major catechin in green tea, contains strong anticancer activity owing to its ability to inhibit tumor growth and metastasis. It does this by inhibiting oncogenic pathways such as PI3K/Akt and Wnt/β-catenin and stimulating tumor suppressor pathways such as p53. EGCG causes cell cycle arrest at the G1 phase, inhibits angiogenesis through inhibition of VEGF expression, and enhances immune responses by controlling cytokine levels. EGCG also acts synergistically with conventional chemotherapy, making it more effective while reducing side effects like oxidative stress(41-43)

5. Berberine (Barberry - Berberis vulgaris)

Fig 9: Barberry - Berberis vulgaris

Berberine, an alkaloid compound isolated from Berberis vulgaris and other medicinal plants, has been studied in-depth for anticancer activity. Berberine causes apoptosis by inducing mitochondrial damage and the production of reactive oxygen species (ROS). It inhibits the PI3K/Akt/mTOR signaling pathway, inhibiting cancer cell survival and growth. Berberine also modulates immune responses by activating T-cells and inhibiting tumor-induced immunosuppression. Berberine has also been shown to reverse multidrug resistance by inhibiting ATP-binding cassette (ABC) transporters, which cause resistance to chemotherapy (44-47)

6.Withaferin A (Ashwagandha - Withania somnifera)

Fig 10: Ashwagandha - Withania som

Withaferin A, a steroidal lactone compound from Withania somnifera (Ashwagandha), has shown strong anticancer activity. It induces apoptosis by activating the p53 cascade and inhibiting nuclear factor-kappa B (NF-κB), reducing inflammation and survival of cancer cells. Withaferin A inhibits metastasis by downregulating epithelial-mesenchymal transition (EMT)-related proteins and inhibiting tumor angiogenesis. It also enhances the efficacy of chemotherapeutic agents with the added benefit of sparing normal tissues from toxicity (48,49).

7.Sulforaphane (Broccoli - Brassica oleracea)

Fig 11: Broccoli - Brassica oleracea

Sulforaphane, a bioactive phytochemical found in broccoli and Brussels sprouts, part of the cruciferous vegetable class, has been shown to have highly potent anticancer activity. Its mechanism is enabled by the induction of phase II detoxification enzymes, such as glutathione S-transferase, which detoxify carcinogens. Sulforaphane also induces apoptosis through caspase activation and inhibition of histone deacetylases (HDACs), which are involved in cancer development (50, 51). Its ability to enhance the immune response and inhibit chronic inflammation makes it a potential agent for cancer prevention and cancer treatment.

9. ADVANTAGES OF HERBAL THERAPY IN CANCER CARE

- Decreased Toxicity:

In contrast to traditional therapies, most herbal agents display selective cytotoxicity—poisoning cancer cells with minimal toxicity to normal tissues. This selectivity decreases frequent side effects like nausea, neuropathy, and immune suppression, enhancing patient tolerance and quality of life.

- Reversal of Drug Resistance:

Some phytochemicals, like quercetin and berberine, inhibit the drug efflux transporters (e.g., P-glycoprotein) commonly involved in chemotherapy resistance. By inhibiting these pathways, plant compounds may reverse cancer cell resistance to standard treatments.

- Synergistic Potential with Standard Therapies:

Herbal drugs can be administered in combination with conventional cancer therapies to improve therapeutic effectiveness. Their synergistic effects can result in decreased doses of chemotherapeutic agents, thus reducing toxicity and preserving or enhancing efficacy.

- Immune System Modulation:

Numerous plant-derived molecules have immunomodulatory activity, which acts to enhance the host's natural defense mechanisms against cancer. By improving immune surveillance and response, the agents are involved in the control and elimination of cancer cells.

10. COMPARATIVE STUDY OF ALLOPATHIC AND HERBAL MEDICINE IN CANCER TREATMENT;

Cancer management involves a broad array of treatment approaches, mainly divided into allopathic (conventional) and herbal (alternative) medicine. Conventional treatments like chemotherapy, radiation therapy, surgery, targeted therapy, and immunotherapy have massive clinical evidences supporting them and are the standard of care in oncology. These modalities can control or destroy tumors but are usually associated with severe side effects such as immunosuppression, fatigue, nausea, and lasting organ toxicity. Herbal medicine, on the other hand, derived from plant-derived compounds such as flavonoids, polyphenols, alkaloids, and terpenoids, has proven to be an adjuvant therapy. Herbal preparations have shown promise in mitigating the side effects of standard treatments, restoring immune competence, and enhancing quality of life.A Health Technology Assessment that examined 14 clinical trials involving 1,965 cancer patients with diverse malignancies—such as breast, lung, ovarian, pancreatic, and stomach cancers—discovered that combining herbal medicine with conventional treatments significantly lowered the risk of death (RR 0.67, 95% CI 0.51–0.90) and minimized the side effects of treatment (RR 0.62, 95% CI 0.54–0.71). Nevertheless, this combined intervention added a critical $19.64 million to healthcare costs annually. Individual herbal supplements like SH003 and Fucoidan have demonstrated potential in clinical applications, with SH003 under evaluation for safety and anti-tumor activity in solid tumors, and Fucoidan showing anti-inflammatory and tumor-inhibiting effects, especially in advanced cancers.In spite of these optimistic reports, authorities firmly advise against using herbal or alternative treatments alone in cancer therapy. A National Cancer Institute study found that breast, lung, and colorectal cancer patients who used alternative medicine alone had much lower survival rates. Indeed, five times more breast cancer and colorectal cancer patients were likely to succumb within five years if they did not undergo conventional allopathic therapy. This emphasizes the vital role of evidence-based medicine to obtain the best results.herbal medicine can have positive adjunctive effects—such as lowering toxicity and enhancing the quality of life for patients—it should not be used to substitute traditional cancer therapies. A unified, individualized strategy blending the benefits of both allopathic and herbal medicine seems to present the most efficient and safest approach to the treatment of cancer.

11. CONCLUSION

Integrative oncology, the integration of traditional cancer therapy and herbal medicine, is promising for maximizing therapeutic benefits with reduced toxicity. Traditional treatments such as chemotherapy, radiotherapy, immunotherapy, and targeted therapy are efficacious but are frequently associated with severe side effects, drug resistance, and low quality of life. Herbal substances like curcumin, resveratrol, quercetin, and berberine possess anticancer activity by inducing apoptosis, immunomodulation, and inhibition of angiogenesis. These herbs can enhance treatment effectiveness, alleviate side effects, and bypass resistance when used as adjuvants. The advantages of integrative strategies have clinical support through the

demonstration of enhanced survival and lowered toxicity. Caution, however, must be exercised because the exclusive use of herbal medications without the use of conventional therapies can lower survival. More large-scale clinical trials should be conducted to create safe, standardized protocols for integration. Finally, an evidence-based patient-centered model that blends mainstream and complementary therapies can improve cancer care, providing a holistic and optimistic future for treatment approaches

REFERENCES

[1] Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209-249. https://doi.org/10.3322/caac.21660

[2] Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394-424. https://doi.org/10.3322/caac.21492

[3] Wang, X., Yang, L., Liu, L., Ran, X., Zhang, H., & Liu, D. (2022). Strategies for overcoming cancer drug resistance: New insights from molecular mechanisms and drug development. Pharmacology & Therapeutics, 239, 108262. https://doi.org/10.1016/j.pharmthera.2021.108262

[4] Deng, G., Cassileth, B. R., & Yeung, K. S. (2021). Complementary therapies in cancer care: An overview. The Oncologist, 26(1), e1-e11. https://doi.org/10.1002/onco.13555

[5] Newman, D. J., & Cragg, G. M. (2020). Natural products as sources of new drugs over the nearly four decades from 1981 to 2019. Journal of Natural Products, 83(3), 770-803. https://doi.org/10.1021/acs.jnatprod.9b01285

[6] Yuan, H., Ma, Q., Ye, L., & Piao, G. (2016). The traditional medicine and modern medicine from natural products. Molecules, 21(5), 559. https://doi.org/10.3390/molecules21050559

[7] Cragg, G. M., & Pezzuto, J. M. (2016). Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive Agents. Medical Principles and Practice, 25(Suppl 2), 41–59.

[8] Anand, P., Sundaram, C., Jhurani, S., Kunnumakkara, A. B., & Aggarwal, B. B. (2008). Curcumin and cancer: An 'old-age' disease with an 'age-old' solution. Cancer Letters, 267(1), 133–164.

[9] Prasad, S., Gupta, S. C., Tyagi, A. K., & Aggarwal, B. B. (2014). Curcumin, a component of golden spice: From bedside to bench and back. Biotechnology Advances, 32(6), 1053–1064

[10] Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015). Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell, 28(6), 690-714.

[11] Pavlakis, N., & Briasoulis, E. (2017). Molecularly targeted therapies in cancer: The case of kinase inhibitors. The Lancet Oncology, 18(4), 474-485.

[12] Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003). 5-fluorouracil: Mechanisms of action and clinical strategies. Nature Reviews Cancer, 3(5), 330-338.

[13] Jordan, M. A., & Wilson, L. (2004). Microtubules as a target for anticancer drugs. Nature Reviews Cancer, 4(4), 253-265.

[14] Baskar, R., Lee, K. A., Yeo, R., & Yeoh, K. W. (2014). Cancer and radiation therapy: Current advances and future directions. International Journal of Medical Sciences, 11(2), 139.

[15] Delaney, G., Jacob, S., Featherstone, C., & Barton, M. (2005). The role of radiotherapy in cancer treatment: Estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer, 104(6), 1129-1137.

[16] Durante, M., & Loeffler, J. S. (2010). Charged particles in radiation oncology. Nature Reviews Clinical Oncology, 7(1), 37-43.

[17] June, C. H., O'Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018). CAR T cell immunotherapy for human cancer. Science, 359(6382), 1361-1365.

[18] Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018). Immune-related adverse events associated with immune checkpoint blockade. New England Journal of Medicine, 378(2), 158-168.

[19] Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., ... & Larson, R. A. (2001). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine, 355(23), 2408-2417.

[20] Hudis, C. A. (2007). Trastuzumab—mechanism of action and use in clinical practice. New England Journal of Medicine, 357(1), 39-51.

[21] Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013). Cancer drug resistance: An

evolving paradigm. Nature Reviews Cancer, 13(10), 714-726.

[22] Osborne, C. K., & Schiff, R. (2011). Mechanisms of endocrine resistance in breast cancer. Annual Review of Medicine, 62, 233-247.

[23] Ali, S., & Coombes, R. C. (2002). Endocrine-responsive breast cancer and strategies for combating resistance. Nature Reviews Cancer, 2(2), 101-112

[24] Attard, G., Parker, C., Eeles, R. A., Schroder, F., Tomlins, S. A., Tindall, D. J., ... & de Bono, J. S. (2016). Prostate cancer. The Lancet, 387(10013), 70-82.

[25] Smith, M. R., Saad, F., Egerdie, B., Sieber, P. R., Tammela, T. L., Ke, C., & Leder, B. Z. (2018). Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. Journal of Urology, 199(2), 379-386.

[26] Appelbaum, F. R. (2007). Hematopoietic-cell transplantation at 50. New England Journal of Medicine, 357(15), 1472-1475

[27] Copelan, E. A. (2006). Hematopoietic stem-cell transplantation. New England Journal of Medicine, 354(17), 1813-1826

[28] Gyurkocza, B., Sandmaier, B. M., & Appelbaum, F. R. (2010). Graft-versus-host disease: Current therapy and future directions. Frontiers in Immunology, 1, 14.

[29] van der Zee, J. (2002). Heating the patient: A promising approach? Annals of Oncology, 13(8), 1173-1184

[30] Dewhirst, M. W., Vujaskovic, Z., Jones, E., & Thrall, D. (2005). Re-setting the biologic rationale for thermal therapy. International Journal of Hyperthermia, 21(8), 779-790.

[31] Dolmans, D. E., Fukumura, D., & Jain, R. K. (2003). Photodynamic therapy for cancer. Nature Reviews Cancer, 3(5), 380-387.

[32] Allison, R. R., & Sibata, C. H. (2010). Oncologic photodynamic therapy photosensitizers: A clinical review. Photodiagnosis and Photodynamic Therapy, 7(2), 61-75.

[33] Aggarwal, B. B., Kunnumakkara, A. B., Harikumar, K. B., Gupta, S. R., Tharakan, S. T., Koca, C., Dey, S., & Sung, B. (2013). Curcumin and cancer cell signaling: A dose-dependent effect. Annals of the New York Academy of Sciences, 1271(1), 1–19. https://doi.org/10.1111/j.1749-6632.2012.06780.x

[34] Jiang, M. C., Yang-Yen, H. F., Yen, J. J., & Lin, J. K. (2019). Curcumin induces apoptosis in immortalized mouse fibroblast NIH 3T3 cells through a reactive oxygen species-dependent mechanism. International Journal of Molecular Sciences, 20(10), 2454. https://doi.org/10.3390/ijms20102454

[35] Baur, J. A., & Sinclair, D. A. (2006). Therapeutic potential of resveratrol: the in vivo evidence. Nature Reviews Drug Discovery, 5(6), 493–506. https://doi.org/10.1038/nrd2060

[36] Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W., Fong, H. H., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., Moon, R. C., & Pezzuto, J. M. (1997). Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275(5297), 218–220. https://doi.org/10.1126/science.275.5297.218

[37] Shukla, Y., & Singh, R. (2011). Resveratrol and cellular mechanisms of cancer prevention. Annals of the New York Academy of Sciences, 1215(1), 1–8. https://doi.org/10.1111/j.1749-6632.2010.05870.x

[38] Davis, W., Lamson, D. W., & Brignall, M. S. (2009). Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. Alternative Medicine Review, 4(5), 304–329.

[39] Li, Y., Yao, J., Han, C., Yang, J., Chaudhry, M. T., Wang, S., Liu, H., & Yin, Y. (2016). Quercetin, inflammation and immunity. Nutrients, 8(3), 167. https://doi.org/10.3390/nu8030167

[40] Hollman, P. C., de Vries, J. H., van Leeuwen, S. D., Mengelers, M. J., & Katan, M. B. (1996). Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. The American Journal of Clinical Nutrition, 62(6), 1276–1282. https://doi.org/10.1093/ajcn/62.6.1276

[41] Yang, C. S., Wang, X., Lu, G., & Picinich, S. C. (2009). Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nature Reviews Cancer, 9(6), 429–439. https://doi.org/10.1038/nrc2641

[42] Bettuzzi, S., Brausi, M., Rizzi, F., Castagnetti, G., Peracchia, G., & Corti, A. (2006). Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Research, 66(2), 1234–1240. https://doi.org/10.1158/0008-5472.CAN-05-1145

[43] Li, Y., Yuan, Y., Meeran, S. M., & Tollefsbol, T. O. (2018). Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast

cancer cells. Molecular Cancer, 9(1), 274. https://doi.org/10.1186/1476-4598-9-274

[44] Sun, Y., Xun, K., Wang, Y., & Chen, X. (2009). A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs. Anti-Cancer Drugs, 20(9), 757–769. https://doi.org/10.1097/CAD.0b013e328330d95b

[45] Wang, Y., Liu, J., Zhang, J., & Liu, B. (2016). Berberine reverses doxorubicin resistance by inhibiting autophagy through the PTEN/Akt/mTOR signaling pathway in breast cancer. Oncology Reports, 35(6), 3661–3669. https://doi.org/10.3892/or.2016.4734

[46] Jiang, S., Wang, Q., & Wang, M. (2021). Berberine reverses multidrug resistance of human breast cancer MCF-7/ADR cells via downregulation of P-glycoprotein expression and inhibition of the PI3K/Akt signaling pathway. Oncology Letters, 21(1), 57. https://doi.org/10.3892/ol.2020.12330

[47] Zhang, X., Zhao, Y., & Zhang, M. (2020). Berberine inhibits P-glycoprotein in multidrug-resistant leukemia cells via downregulation of NF-κB and MAPK signaling pathways. Biomedicine & Pharmacotherapy, 131, 110673. https://doi.org/10.1016/j.biopha.2020.110673.

[48] Stan, S. D., Hahm, E. R., Warin, R., & Singh, S. V. (2008). Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Research, 68(18), 7661–7669. https://doi.org/10.1158/0008-5472.CAN-08-1510

[49] Vyas, A. R., Singh, S. V., & Aggarwal, B. B. (2012). Withaferin A suppresses the epithelial-mesenchymal transition in human breast cancer cells. Oncotarget, 3(6), 585–596. https://doi.org/10.18632/onc

[50] Zhang, Y., Talalay, P., Cho, C. G., & Posner, G. H. (2006). A major inducer of anticarcinogenic protective enzymes from broccoli: Isolation and elucidation of structure. Proceedings of the National Academy of Sciences, 89(6), 2399–2403. https://doi.org/10.1073/pnas.89.6.2399

[51] Clarke, J. D., Dashwood, R. H., & Ho, E. (2008). Multi-targeted prevention of cancer by sulforaphane. Cancer Letters, 269(2), 291–304. https://doi.org/10.1016/j.canlet.2008.04.018

[52] Bisht, R., Joshi, B., & Joshi, H. (2016). Phytomedicine in the treatment of cancer: A health technology assessment. Journal of Clinical and Diagnostic Research, 10(2), ZE10–ZE15. https://doi.org/10.7860/JCDR/2016/17334.7274

[53] Johnson, S. B., Park, H. S., Gross, C. P., & Yu, J. B. (2018). Use of alternative medicine for cancer and its impact on survival. JAMA Oncology, 4(10), 1375–1381. https://doi.org/10.1001/jamaoncol.2018.2487

[54] Lee, H. W., Cheon, C., & Ko, S. G. (2024). Safety of the herbal medicine SH003 in patients with solid cancer: A multi-center, single-arm, open-label, dose-escalation phase I study. Integrative Cancer Therapies, 23, 15347354241293451. https://doi.org/10.1177/15347354241293451

[55] Oh, S., Kim, K. Y., & Lee, J. H. (2024). Fucoidan-induced anti-inflammatory and anti-cancer effects in advanced cancer patients. Marine Drugs, 22(1), 15. https://doi.org/10.3390/md22010015